Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity

American Journal of Gastroenterology

Volumn 105, Issue 10, 2010, Pages 2235-2243

  Scully, Paul ^a   McKernan, Declan P ^a   Keohane, John ^a   Groeger, David ^a   Shanahan, Fergus ^a   Dinan, Timothy G ^a   Quigley, Eamonn M M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHRONIC FATIGUE SYNDROME; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE ASSOCIATION; FEMALE; FIBROMYALGIA; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; ADULT; BLOOD; COMPLICATION; MIDDLE AGED; NONPARAMETRIC TEST;

ADULT; CYTOKINES; FATIGUE SYNDROME, CHRONIC; FEMALE; FIBROMYALGIA; HUMANS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; PREMENSTRUAL SYNDROME; STATISTICS, NONPARAMETRIC;

EID: 77957844957     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.159     Document Type: Article

References (37)

1. Drossman DA, Camilleri M, Mayer EA et al. AGA technical review onirritable bowel syndrome. Gastroenterology 2002; 123: 2108-31. (Pubitemid 35408332)
2. Quigley EM, Bytzer P, Jones R et al. Irritable bowel syndrome: the burdenand unmet needs in Europe. Dig Liver Dis 2006; 38: 717-23. (Pubitemid 44362188)
3. Thompson WG, Longstreth GF, Drossman DA et al. Functional boweldisorders and functional abdominal pain. Gut 1999; 45 (Suppl 2): II43-7
4. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia.Gastroenterology 1994; 107: 271-93.
5. Halpert A, Drossman D. Biopsychosocial issues in irritable bowel syndrome. J Clin Gastroenterol 2005; 39: 665-9. (Pubitemid 41177083)
6. Sartor RB. Cytokines in intestinal inflammation: pathophysiological andclinical considerations. Gastroenterology 1994; 106: 533-9.
7. Dinan TG, Quigley EM, Ahmed SM et al. Hypothalamic-pituitary-gut axisdysregulation in irritable bowel syndrome: plasma cytokines as a potentialbiomarker? Gastroenterology 2006; 130: 304-11.
8. Liebregts T, Adam B, Bredack C et al. Immune activation in patients withirritable bowel syndrome. Gastroenterology 2007; 132: 913-20. (Pubitemid 46440872)
9. O'Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacteriumin irritable bowel syndrome: symptom responses and relationship tocytokine profiles. Gastroenterology 2005; 128: 541-51. (Pubitemid 40585355)
10. Clarke G, Quigley EM, Cryan JF et al. Irritable bowel syndrome: towardsbiomarker identification. Trends Mol Med 2009; 15: 478-89.
11. de Wied D, Diamant M, Fodor M. Central nervous system effects of theneurohypophyseal hormones and related peptides. Frontiers Neuroendocrinol 1993; 14: 251-302. (Pubitemid 23321822)
12. Dinan TG. Glucocorticoids and the genesis of depressive illness. A psychobiologicalmodel. Br J Psychiatry 1994; 164: 365-71.
13. Ma XM, Lightman SL, Aguilera G. Vasopressin and corticotropin- releasinghormone gene responses to novel stress in rats adapted to repeatedrestraint. Endocrinology 1999; 140: 3623-32. (Pubitemid 30645417)
14. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediatedinflammation. New Engl J Med 1995; 332: 1351-62.
15. Dunn AJ. Systemic interleukin-1 administration stimulates hypothalamicnorepinephrine metabolism parallelling the increased plasma corticosterone. Life Sci 1988; 43: 429-35.
16. Whitehead WE, Palsson O, Jones KR. Systematic review of the co-morbidityof irritable bowel syndrome with other disorders: what are the causesand implications? Gastroenterology 2002; 122: 1140-56. (Pubitemid 34267295)
17. Gaynes BN, Drossman DA. The role of psychosocial factors in irritable bowelsyndrome. Bailliere's Best Pract Res Clin Gastroenterol 1999; 13: 437-52.
18. Riedl A, Schmidtmann M, Stengel A et al. Somatic co-morbidities ofirritable bowel syndrome: a systematic analysis. J Psychosomatic Res 2008; 64: 573-82.
19. Markowitz M, Harris W, Ricci J-F et al. Co-morbid conditions in patientswith irritable bowel syndrome: data from a national IBS awareness registry.Gastroenterology 2001; 120: A:23120
20. Longstreth GF, Wolde-Tsadik G. Irritable bowel-type symptoms in HMOexaminees. Prevalence, demographics, and clinical correlates. Dig Dis Sci 1993; 38: 1581-9. (Pubitemid 23271410)
21. Walker EA, Gelfand AN, Gelfand MD et al. Chronic pelvic pain and gynecologicalsymptoms in women with irritable bowel syndrome. J PsychosomaticObstetrics Gynaecol 1996; 17: 39-46. (Pubitemid 26144133)
22. Miller AR, North CS, Clouse RE et al. The association of irritable bowelsyndrome and somatization disorder. Ann Clin Psychiatry 2001; 13: 25-30.
23. Wolfe F, Smythe HA, Yunus MB et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of theMulticenter Criteria Committee. Arthritis Rheumatism 1990; 33: 160-72.
24. Fukuda K, Straus SE, Hickie I et al. The chronic fatigue syndrome: acomprehensive approach to its definition and study. International ChronicFatigue Syndrome Study Group. Ann Intern Med 1994; 121: 953-9. (Pubitemid 24370860)
25. Association AP. Diagnostic and Statistical Manual of Mental Disorders, 4thedn, American Psychiatric Assocation Press: Washington, DC, 1994.
26. Dinan TG, Clarke G, Quigley EM et al. Enhanced cholinergic-mediated increasein the pro-inflammatory cytokine IL-6 in irritable bowel syndrome:role of muscarinic receptors. Am J Gastroenterol 2008; 103: 2570-6.
27. Barreau F, Ferrier L, Fioramonti J et al. Neonatal maternal deprivationtriggers long term alterations in colonic epithelial barrier and mucosalimmunity in rats. Gut 2004; 53: 501-6. (Pubitemid 38372973)
28. O'Mahony SM, Marchesi JR, Scully P et al. Early life stress alters behavior,immunity, and microbiota in rats: implications for irritable bowel syndromeand psychiatric illnesses. Biol Psychiatry 2009; 65: 263-7.
29. Fitzgerald P, Cassidy Eugene M, Clarke G et al. Tryptophan catabolism infemales with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity. NeurogastroenterolMotil 2008; 20: 1291-7.
30. Wirleitner B, Neurauter G, Schrocksnadel K et al. Interferon- gammainducedconversion of tryptophan: immunologic and neuropsychiatricaspects. Curr Med Chem 2003; 10: 1581-91.
31. Sperber AD, Carmel S, Atzmon Y et al. Use of the Functional BowelDisorder Severity Index (FBDSI) in a study of patients with theirritable bowel syndrome and fibromyalgia. Am J Gastroenterol 2000; 95: 995-8. (Pubitemid 30196736)
32. Sperber AD, Carmel S, Atzmon Y et al. The sense of coherence index andthe irritable bowel syndrome. A cross-sectional comparison amongirritable bowel syndrome patients with and without coexisting fibromyalgia,irritable bowel syndrome non-patients, and controls. Scand J Gastroenterol 1999; 34: 259-63. (Pubitemid 29192996)
33. Clauw DJ. The pathogenesis of chronic pain and fatigue syndromes, withspecial reference to fibromyalgia. Med Hypotheses 1995; 44: 369-78.
34. Sperber AD, Atzmon Y, Neumann L et al. Fibromyalgia in the irritablebowel syndrome: studies of prevalence and clinical implications. Am JGastroenterol 1999; 94: 3541-6.
35. Holmes GP, Kaplan JE, Gantz NM et al. Chronic fatigue syndrome: a workingcase definition. Ann Intern Med 1988; 108: 387-9.
36. Loizzo A, Loizzo S, Lopez L et al. Naloxone prevents cell-mediated immunealterations in adult mice following repeated mild stress in the neonatalperiod. Br J Pharmacol 2002; 135: 1219-26. (Pubitemid 34259124)
37. Vandvik PO, Wilhelmsen I, Ihlebaek C et al. Co-morbidity of irritablebowel syndrome in general practice: a striking feature with clinical implications. Aliment Pharmacol Ther 2004; 20: 1195-203 (Pubitemid 39657954)